Host immunological factors enhancing mortality of young adults during the 1918 influenza pandemic

Julie L. McAuley*, Katherine Kedzierska¹, Lorena E. Brown¹ and G. Dennis Shanks²,³

¹ Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, ² Australian Army Malaria Institute, Enoggera, QLD, Australia, ³ School of Population Health, University of Queensland, Brisbane, QLD, Australia

During the 1918 influenza pandemic, healthy young adults unusually succumbed to infection and were considered more vulnerable than young children and the elderly. The pathogenesis of this pandemic in the young adult population remains poorly understood. As this population is normally the least likely to die during seasonal influenza outbreaks, thought to be due to their appropriate pre-existing and robust immune responses protecting them from infection, we sought to review existing literature for immunological reasons for excessive mortality during the 1918 pandemic. We propose the novelty of the H1N1 pandemic virus to an H1N1 naïve immune system, the virulence of this virus, and dysfunctional host inflammatory and immunological responses, shaped by past influenza infections could have each contributed to their overall susceptibility. Additionally, in the young adult population, pre-exposure to past influenza infection of different subtypes, such as a H3N8 virus, during their infancy in 1889–1892, may have shaped immunological responses and enhanced vulnerability via humoral immunity effects with cross-reactive or non-neutralizing antibodies; excessive and/or ineffective cellular immunity from memory T lymphocytes; and innate dysfunctional inflammation. Multiple mechanisms likely contributed to the increased young adult mortality in 1918 and are the focus of this review.

Keywords: influenza, pandemic, 1918, pathogenesis, mortality

Introduction

The 1918–1919 influenza pandemic caused an estimated 50 million deaths (1). In three distinct waves, the pandemic infected a third of the world’s population, with the majority of the deaths occurring during the second wave in late 1918 (2, 3). Disease was characterized by unique, and to date poorly understood, epidemiological and clinical aspects. Victims died either from direct viral infection of the lung (4, 5), or most commonly from secondary bacterial pneumonia (6–8). Unusually, healthy young adults were more likely to die than young children and the elderly, two populations normally most vulnerable during influenza A virus (IAV) outbreaks (9). Fatal cases in the 1918 pandemic peaked in the 1889–92 birth cohorts, corresponding to approximately 28-year-olds (2, 10, 11), a pattern that was observed across the world (9, 12). The extraordinary mortality of young adults during the 1918 influenza pandemic is not currently understood.

Similar to the 1918 pandemic, the 2009 IAV pandemic caused more severe and fatal cases in 30- to 50-year-olds, which constituted up to one-third of patients in hospitals (13–15). Young adults had...
two to four times the risk of severe outcomes from infection with this virus (H1N1pdm09) than those infected with circulating seasonal influenza (16). The majority of H1N1pdm09 infections caused a self-limited disease and the pandemic was considered the mildest on record. Until we understand the causes of enhanced illness of the young adult population during the 1918 and 2009 IAV pandemics, we are unlikely to be able to realistically estimate the impact of future pandemics. While no single explanation will be relevant to every mortality event in the young adults, we need to understand how their innate and acquired immune status may have combined with viral virulence to enhance mortality.

**Excessive Innate Host Responses Contribute to Influenza Immunopathology**

Initial leukocyte infiltration into the lung parenchyma is essential for resolution of virus infection, yet dysregulation of the infiltrating effector cells be a major factor in disease (17, 18). A hallmark for resolution of virus infection, yet dysregulation of the infiltrating effector cells causes a self-limited disease and the pandemic was considered the mildest on record. Until we understand the causes of enhanced illness of the young adult population during the 1918 and 2009 IAV pandemics, we are unlikely to be able to realistically estimate the impact of future pandemics. While no single explanation will be relevant to every mortality event in the young adults, we need to understand how their innate and acquired immune status may have combined with viral virulence to enhance mortality.

**Humoral Immunity Enhancing Susceptibility of the Young Adult Population in 1918**

Influenza A virus infections during childhood typically induce B-cell memory responses that can adapt to produce antibody protecting against future infection by divergent drift strains of IAVs (31) (Figure 1). Such virus neutralizing antibody responses are typically directed toward epitopes on the globular head of the virus surface glycoprotein hemagglutinin (HA) and can be long-lived. This longevity was particularly evidenced by protection of the elderly against H1N1pdm09 infection, which was attributed to antibodies raised during pre-1960s exposure to a virus of the pandemic lineage (31). The elderly may have survived better than young adults during the 1918 pandemic as they may have been previously exposed to other H1 IAVs (32).

In the absence of specific-neutralizing antibodies, other antibodies that are normally immuno-subdominant can be induced and may be cross-reactive against different IAV subtypes. One such target of subdominant cross-reactive antibody is the viral ion channel protein, M2. The M2 protein is expressed on the virion surface but does not protrude to the level of other glycoproteins, making it a poor viral neutralization target. M2 is more accessible on the surface of infected cells and is thought to enable direct killing of infected cells by antibody-dependent cellular cytotoxicity (ADCC) mechanisms (33–35). Whether anti-M2 antibodies were important during the 1918 pandemic is unknown. Another target of subdominant cross-reactive antibodies are those directed toward the HA stalk (36). Antibodies to the HA-stalk and 1918-virus challenge compared to infected wild-type mice (27, 28). The type-1 interferons act on INF-α/β receptors to activate the antiviral signaling cascade, resulting in the production of antiviral proteins, such as MxA (Mx1 in mice). Mice genetically deficient in Mx1, interleukin-1 receptor (IL-1R), or IFNα receptor (IFNAR) exhibited increased viral load and pulmonary inflammation compared to wild-type mice (28–30). The molecular signatures of mice surviving 1918-virus infection reveal that the action of interferon via upregulation of genes involved with apoptosis, ROS production, and cell migration, together with downregulation of genes encoding cytokine and chemokine production associated with viral pathlogy, such as IL-6 and TNF, is critical to survival (29). As such, type-I IFNs contribute to both resolution of viral load and suppression of immunopathology caused by IAV infections. Inflammatory responses in animal infection models otherwise immunologically naive toward IAV show that enhancement of inflammation in young adults could have been a major contributor to mortality during the 1918 influenza pandemic.
In many animal studies, it has been shown that anti-M2 and HA-stalk antibodies induced by vaccination or passive transfer result in viral clearance and protection (35, 38, 40–45). In macaques, weakly immunogenic vaccines did not lead to robust ADCC responses and as such did not contribute to vaccination efficacy (46). Human studies have now revealed cross-reactive HA-stalk antibodies that are broadly neutralizing against divergent IAV strains (e.g., H1N1, H3N2, H5N1, and H7N9) and may protect from infection (41, 45, 47). However, it is important to note that not all individuals are capable of producing HA-stalk antibodies (48). Plasmablasts capable of secreting HA-stalk-specific antibodies have been isolated from healthy adults after H1N1pdm09 vaccination. These cells were produced from already existing memory B cells, which were presumably primed by previous IAV infections (41, 49), a scenario recapitulated by mice in sequential infections (50).

During the 1918 IAV pandemic, prior exposure to previously circulating influenza viruses would have shaped the memory B cell population to produce a landscape of both direct and cross-protective antibody responses (51) that may have resulted in protection from infection (Figure 1B). Young adults devoid of sufficient memory B cells capable of producing direct and cross-reactive antibodies, due to either their inability to mount such responses or from lack of prior IAV infections, may have fared much worse in 1918 (Figure 1C).

The phenomenon of vaccine-associated enhanced respiratory disease is reminiscent of that seen in children vaccinated with inactivated RSV or measles virus following exposure to a heterotypic virus, who subsequently suffered enhanced respiratory disease or atypical measles with severe disease (55–57). Reasons for dire outcome include the quality of the antibody elicited toward the virus, the presence of large amounts of non-neutralizing antibody at the time of viral replication, and antibody-mediated activation of the classic complement cascade (56). The young adult population of the 1918 pandemic may have had prior exposure to a double-heterogenic H3N8 IAV during their childhood (32), and may have developed a cross-reactive humoral immunity. It is possible that in some young adults, the cross-reactive antibody responses produced after infection with...
the 1918 virus actually enhanced subsequent pulmonary disease, for reasons similar to those observed for RSV and measles (55–57). This may be why, compared to children, the young adults were more vulnerable to the 1918 IAV infection.

Whether infection during the initial wave of the pandemic in early 1918 protected one from illness in subsequent waves of the pandemic during late 1918–1919 is not clear despite extensive study (12, 58–61). Young adults infected with the pandemic virus in early 1918 may have had a recall of the memory B cell population boosting the production of both direct and cross-protective antibody responses (51). Subsequent infection during the second or third wave of the pandemic may have resulted in further cross-reactive responses that may have induced ADCC and/or inflammatory disease. In Australian soldiers who could be followed individually, infection in early 1918 appeared to protect against death, but not illness during the subsequent wave occurring later during the 1918 pandemic (12). Additionally, recent Canadian studies showing that seasonal influenza vaccine apparently enhanced illness rates during the 2009 pandemic (62).

A recent study (32) proposes that individuals born earlier than ~1890–1900 would have had neutralizing antibodies against the 1918 pandemic virus, induced by an emerging H1N1 virus in 1830, or an H1N8 virus in 1847 (32). Those born at the time of the 1889–92 H3N8 pandemic, or shortly thereafter, would not have such neutralizing antibodies and would be highly susceptible to 1918-virus infection. It is further postulated that an H1N8 virus re-emerged in 1900 and may have allowed the children in 1918 some degree of protection. If this did indeed occur, it would account for the troughs in the mortality curves in the young (5–15 years) and older (50–80 years) populations during the 1918 pandemic (32). Similarly, during the 2009 pandemic, about one-third of people born before 1950 had some immunity to the H1N1pdm09 virus, perhaps due to childhood exposure to an antigenically similar IAV (62, 63).

Cross-Reactive CD8+ T Cell Immunity: Implications for Disease

Pre-existing memory CD8+ T cells established via previous IAV infections can cross-react with common epitopes presented by class I human leukocyte antigen (HLA) complexes on antigen presenting cells and promote rapid viral clearance. Animal (64, 65) and human studies (64, 66–68) have shown that CD8+ T cell-mediated immunity can be directed against highly conserved antigens among different IAV subtypes. More recently, non-conserved peptide epitopes that vary at residues other than those that anchor the peptide within the binding cleft of the HLA can still induce cross-reactive T cells (69). Memory CD8+ T cells can ameliorate infection by heterologous IAVs; however, substantial mutation in IAV peptide epitopes may lead to ineffective recruitment of cytotoxic CD8+ T cells crucial for viral clearance. Alternatively, a lack of capacity to mount any CD8+ T cell response could be equally problematic. The recruitment of cross-reactive CD8+ T cells against IAV varies across different ethnicities and has been shown to be dependent upon the capability of expressing the HLA class I alleles that present conserved IAV peptides to elicit cross-protective CD8+ T cells (64).

Young adults who had survived infection by an IAV in 1890 should have had robust priming of memory CD8+ T cells that conferred some protection from lethal disease during the 1918 pandemic, provided these cells were periodically boosted by intra-pandemic IAV infection (32). Upon infection with the 1918 H1N1 IAV cross-reactive T cell responses would have been rapidly recalled in these individuals and may have protected against their death (70) (Figure 2). Recent studies have shown cross-reactive CD8+ T cell memory pools, generated by previous infection (s) with IAVs could provide some protection against H7N9 IAV infection (64). During 2009, the elderly population had a low infection rate compared to children and young adults, which was thought to be due to T cell immunity and neutralizing antibodies against the extremely conserved immune-dominant epitopes on viral proteins in the 2009 and 1918 H1N1 pandemic strains. Partial cross-reactivity with seasonal H1N1 IAVs that circulated in the 1930s when the elderly population would have been children may have also contributed (69, 71).

Caveats exist for the protective role described for cross-reactive CD8+ T cells. Cross-reactive CD8+ T cells cannot protect the host from initial infection; their target is an infected cell and they must be recruited to the site of infection after recall stimulation. If the heterologous IAV infecting the host presents a strong stimulus via PRRs that trigger excessive inflammatory responses and recruits an overwhelming number of cross-reactive CD8+ T cells, the resulting immunopathology may overwhelm any beneficial effects (10, 72) (Figure 2Bii). In addition, dysfunctional priming of CD8+ T cells may explain why the second wave of the 1918 pandemic appeared more virulent than the first. It has been postulated that the second wave of the 1918 pandemic was caused by a virus that had evolved toward a more pathogenic phenotype than the initially emerging H1N1 IAV (73). However, CD8+ T cells reactive for the immunodominant IAV nucleoprotein (NP) and matrix-1 (M1) produced during first wave of the 1918 pandemic and subsequently recalled upon infection during the second wave in late 1918 may have contributed to an overexuberant inflammatory response enhancing disease severity (17, 58, 64, 74). As the ability to mount CD8+ T cell responses is linked to highly polymorphic HLA expression, healthy young adults infected in 1918 may have induced highly variable responses that could have been to their detriment due to recruitment of a plethora of non-cross-reactive CD8+ T cells (Figure 2Biii). Additionally, the robustness of the immune system in the young adult population as well as their pre-existing memory CD8+ T cell repertoire may have contributed to the vulnerability of this population over children, who may mounted a smaller repertoire of more specific CD8+ T cells toward the pandemic virus. Given a larger number of previous IAV exposures, the elderly may have mounted a more diverse cross-reactive CD8+ T cell response, but may have achieved clearance of infection without excessive cellular recruitment due to a decreased ability to recruit cells compared to the young adult population. Compared to young adults, the infected elderly CD8+ T cell response to the 1918 H1N1 virus may not have enhanced the pathophysiology of the disease and as such, may have been more effective toward clearing the viral infection.
Concluding Remarks

The causes of extreme mortality in the young adult population during the 1918 pandemic are still uncertain. Childhood exposure to heterotypic IAV may have shaped humoral and adaptive immunological responses that contributed to the young adult population’s enhanced disease outcomes. Ethnicity resulting in lack of appropriate immunological responses to conserved antigenic sites in the 1918 pandemic IAV may have also contributed to the mortality. PRRs may have induced over-exuberant inflammatory responses enhancing lung pathology and disease. Such mechanisms may collectively explain the increased mortality of young adults during the 1918 influenza pandemic. The enhanced illness in H1N1pdm2009 H1N1-infected young adults demonstrates that we still do not completely understand factors that enhance human vulnerability. We must continue to explore transmission models, virulence factors, and host responses to infection to better understand the pathophysiology of influenza if we are to diminish the impact of any new, highly pathogenic pandemic virus.

Funding

JM is funded by the National Health and Medical Research Council of Australia (NHMRC) Project Grant 1026619; KK is a CDF2 NHMRC Fellow; KK and LB receive funding from NHMRC Program Grant 1071916; and GS is funded by the Australian Defence Force.

Author Note

The opinions expressed are those of the authors and do not necessarily reflect those of the Australian Defence Force.

References

1. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet (2006) 368:2211–8. doi:10.1016/S0140-6736(06)69895-4
2. Taubenberger JK, Morens DM. 1918 influenza: the mother of all pandemics. Emerg Infect Dis (2006) 12:15–22. doi:10.3201/eid1209.05-0979
3. Frost W. The epidemiology of influenza. JAMA (1919) 73:313–8. doi:10.1001/jama.1919.02610310007003
4. Opie EL, Blake FG, Small JC, Rivers TM. Epidemic Respiratory Disease: The Pneumonias and Other Infections of the Respiratory Tract Accompanying Influenza and Measles. St Louis: C. V. Mosby Company (1921).
5. Conner LA. The symptomatology and complications of influenza. JAMA (1919) 73:321–5. doi:10.1001/jama.1919.02610310015005
6. Abrahams A, Hallows N, French H. A further investigation into influenza-pneumococcal and influenza-streptococcal septicaemia. *Lancet* (1919) 193(4975):1–11. doi:10.1016/S0140-6736(01)22115-1

7. Chicking HT, Park JH. *Staphylococcus aureus* pneumonia. *JAMA* (1919) 72:617–26. doi:10.1001/jama.1919.0261090001001

8. Park WH. Bacteriology of recent pandemics of influenza and complicating infections. *JAMA* (1919) 73:318–21. doi:10.1001/jama.1919.0261030102004

9. Shanks GD, Brundage JF. Pathogenic responses among young adults during the 1918 influenza pandemic. *Emerg Infect Dis* (2012) 18:201–7. doi:10.3201/eid1802.100242

10. Gagnon A, Miller MS, Hallman SA, Bourbeau R, Herring DA, Earn DJ, et al. Age-specific mortality during the 1918 influenza pandemic: unravelling the mystery of high young adult mortality. *PLoS One* (2013) 8:e69586. doi:10.1371/journal.pone.0069586

11. Wilson N, Oliver J, Rice G, Summers JA, Baker MG, Waller M, et al. Age-specific mortality during the 1918–19 influenza pandemic and possible relationship to the 1889–92 influenza pandemic. *J Infect Dis* (2014) 210(6):993–9. doi:10.1093/infdis/jiu191

12. Shanks GD, Russell T, Brundage JF. Epidemiological isolation causing variable mortality in Island populations during the 1918–1920 influenza pandemic. *Influenza Other Respir Viruses* (2012) 6:417–23. doi:10.1016/j.influenza.2011.00332.x

13. Kumar A, Zarychanski R, Pinto R, Klassen TP, Marshall J, Lacroix J, et al. Critically ill patients with 2009 influenza A (H1N1) infection in Canada. *JAMA* (2009) 302:1872–9. doi:10.1001/jama.2009.1496

14. Investigators AI, Webb SA, Pettila V, Seppelt I, Bellomo R, Bailey M, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. *JAMA* (2009) 302:1878–85. doi:10.1001/jama.2009.1496

15. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al. Protective immunity in human cases of influenza A (H7N9) virus infection. *Nature* (2014) 509:284–9. doi:10.1038/nature13194

16. Reed C, Chaves SS, Perez A, D'Mello T, Daily Kirley P, Aragon D, et al. Communication of the 1918 influenza A virus to stem region-specific neutralizing antibodies. *Science* (2015) 348:921–2. doi:10.1126/science.aac4633

17. A. brahams A, Hallows N, French H. A further investigation into influenza-pneumococcal and influenza-streptococcal septicaemia. *Lancet* (1919) 193(4975):1–11. doi:10.1016/S0140-6736(01)22115-1

18. Perrone LA, Belser JA, Wadford DA, Katz JM, Tumpey TM. Inducible nitric oxide contributes to viral pathogenesis following highly pathogenic influenza virus infection in mice. *J Infect Dis* (2013) 207:1576–84. doi:10.1093/infdis/jit062

19. Belisle SE, Tisoncik JR, Korth MJ, Carter VS, Proll SC, Swayne DE, et al. Genomic profiling of tumor necrosis factor alpha (TNF-α) receptor and interleukin-1 receptor knockout mice reveals a link between TNF-α signaling and increased severity of 1918 pandemic influenza virus infection. *J Virol* (2010) 84:12576–88. doi:10.1128/JVI.01310-10

20. Cillooniz C, Pantin-Jackwood MJ, Ni C, Carter VS, Korth MJ, Swayne DE, et al. Molecular signatures associated with Mx1-mediated resistance to highly pathogenic influenza virus infection: mechanisms of survival. *J Virol* (2012) 86:2437–46. doi:10.1128/JVI.01615-11

21. Arimori Y, Nakamura Y, Yamada H, Shibata K, Maeda N, Kase T, et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. *Antiviral Res* (2013) 99:230–7. doi:10.1016/j.antiviral.2013.05.007

22. Manicassamy B, Medina RA, Hui R, Tishbne T, Sertz S, Nistal-Villan E, et al. Prevention of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1-based vaccines. *PLoS Pathog* (2010) 6:e1000745. doi:10.1371/journal.ppat.1000745

23. Worobey M, Han GZ, Rambaut A. Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus. *Proc Natl Acad Sci U S A* (2014) 111:8107–12. doi:10.1073/pnas.1324197111

24. Jegaskanda S, Job ER, Kramski M, Laurie K, Istitman G, de Rose R, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. *J Immunol* (2013) 190:1387–48. doi:10.4049/jimmunol.1201574

25. Waffarn EE, Baumgarth N. Protective B cell responses to flu—not flu! *J Immunol* (2011) 186:3823–9. doi:10.4049/jimmunol.1002090

26. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. *J Immunol* (2004) 172:5598–605. doi:10.4049/jimmunol.172.9.5598

27. Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. *Curr Opin Virol* (2013) 3:521–30. doi:10.1016/j.coviro.2013.07.007

28. Belisle SE, Tisoncik JR, Korth MJ, Carter VS, Proll SC, Swayne DE, et al. Broadly cross-reactive antibodies dominate the human B cell response against highly pathogenic influenza antibodies. *Nature* (2012) 489:566–70. doi:10.1038/nature11371

29. Jegaskanda S, Winifurtner JT, Friedrich TC, Kent SJ. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. *J Virol* (2013) 87:5512–22. doi:10.1128/JVI.03030-12

30. Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, et al. Complement-dependent lysis of influenza A virus-infected cells by broadly cross-reactive human monoclonal antibodies. *J Virol* (2011) 85:13463–7. doi:10.1128/JVI.05193-11

31. Song A, Myojo K, Lautenslager J, Harada D, Miura T, Suzuki K, et al. Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates. *Antiviral Res* (2014) 111:60–8. doi:10.1016/j.antiviral.2014.08.016

32. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Su J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J Exp Med* (2011) 208:181–93. doi:10.1084/jem.20101352

33. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, et al. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. *PLoS Pathog* (2010) 6:e1000796. doi:10.1371/journal.ppat.1000796

34. Harris AK, Meyerson JR, Matsuoka Y, Kuybeda O, Moran A, Bliss D, et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus. *Proc Natl Acad Sci U S A* (2013) 110:4592–7. doi:10.1073/pnas.1214913110

35. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. *Science* (2011) 333:850–6. doi:10.1126/science.1205669
45. Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest (2015) 125:1255–68. doi:10.1172/JCI74374

46. Jegaskanda S, Amarasesha TH, Laurie KL, Tan BX, Butler J, Parsons MS, et al. Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques. J Virol (2013) 87:13706–18. doi:10.1128/JVI.01866-13

47. Nachbarger R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 virus in humans. J Virol (2014) 88:13260–8. doi:10.1128/JVI.02133-14

48. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 453:667–71. doi:10.1038/nature06890

49. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, et al. Fr

50. Krammer F, Pica N, Hai R, Tan GS, Zheng NY, Andrews S, et al. Pre-existing antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol (2012) 86:10302–7. doi:10.1128/JVI.01336-12

51. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, et al. Antibody landscapes after influenza virus infection or vaccination. Science (2014) 346:996–1000. doi:10.1126/science.1256427

52. Quinones-Parra S, Loh L, Brown LE, Kedzierska K, Valkenburg SA. Universal antibodies are boosted following sequential infection with seasonal and pandemic (2009) A/H1N1 influenza virus. Proc Natl Acad Sci U S A (2012) 109:9047–52. doi:10.1073/pnas.1118979109

53. Krammer F, Pica N, Hai R, Tan GS, Palese P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol (2012) 86:10302–7. doi:10.1128/JVI.01336-12

54. Gauger PC, Vincent AL, Loving CL, Henningson JN, Lager KM, Janke BH, et al. Transgenic mice lacking class I immune complexes in enhanced respiratory syncytial virus disease. J Virology (2014) 88:13260–8. doi:10.1128/JVI.02133-14

55. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Am J Prev Med (2006) 31:357–60. doi:10.1016/j.amepre.2006.04.005

56. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med (2013) 5:200ra114. doi:10.1126/scitranslmed.3003666

57. Gauger PC, Vincent AL, Loving CL, Henningson JN, Langer KM, Janke BH, et al. Kinetics of lung lesion development and pro-inflammatory cytokine response in pigs with vaccine-associated enhanced respiratory disease induced by challenge with pandemic (2009) A/H1N1 influenza virus. Vet Pathol (2012) 49:900–12. doi:10.1177/0300985812439724

58. Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA (1967) 202:1075–80. doi:10.1001/jama.1967.03130250057008

59. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu YC, Denholm JT, et al. Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza virus. Proc Natl Acad Sci U S A (2010) 107:12599–604. doi:10.1073/pnas.1006936107

60. Berri F, Le VB, Jandrot-Perrus M, Lina B, Riteau B. Switch from protective to adverse inflammation during influenza: viral determinants and hematostasis are caught as culprits. Cell Mol Life Sci (2014) 71:885–98. doi:10.1007/s00018-013-1479-x

61. Shank GD, MacKenzie A, Waaler M, Brundage JE. Low but highly variable mortality among nurses and physicians during the influenza pandemic of 1918-1919. Influenza Other Respir Viruses (2011) 5:213–9. doi:10.1111/j.1750-2659.2010.00195.x

62. Hancock K, Veggulla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med (2009) 361:1945–52. doi:10.1056/NEJMoa0906453

63. Fisman DN, Savage R, Gubbay J, Achoru C, Akwar H, Farrell DJ, et al. Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med (2009) 361:2001–1. doi:10.1056/NEJMc0907256

64. Quinones-Parra S, Grant E, Loh L, Nguyen TH, Campbell KA, Tong SY, et al. Preexisting CD8+ T-cell immunity to the H7N9 Influenza A Virus varies across ethnicities. Proc Natl Acad Sci U S A (2014) 111:1049–54. doi:10.1073/pnas.132229111

65. Bender BS, Croghen T, Zhang L, Small PA Jr. Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med (1992) 175:1143–5. doi:10.1084/jem.175.4.1143

66. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland family study participants during the H2N2 pandemic of 1957: an experiment of nature. Infect Dis (2006) 193:49–53. doi:10.1086/498980

67. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 309:13–7. doi:10.1056/NEJM198307073090103

68. Sridhar S, Begom S, Bermingham A, Hoschner K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med (2013) 19:1305–12. doi:10.1038/nmm.3350

69. Gras S, Kedzierski L, Valkenburg SA, Laurie K, Liu Y, Denholm JT, et al. Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A (2010) 107:12599–604. doi:10.1073/pnas.1007270107

70. Brundage JE. Cases and deaths during influenza pandemics in the United States. Am J Prev Med (2006) 31:252–6. doi:10.1016/j.amepre.2006.04.005

71. Xu R, Eikert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 328:357–60. doi:10.1126/science.1186430

72. Berri F, Le VB, Jandrot-Perrus M, Lina B, Riteau B. Switch from protective to adverse inflammation during influenza: viral determinants and hematostasis are caught as culprits. Cell Mol Life Sci (2014) 71:885–98. doi:10.1007/s00018-013-1479-x

73. Sheng ZM, Chertow DS, Ambroggio S, McCull C, Przygodzki RM, Cunningham RE, et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci U S A (2011) 108:16416–21. doi:10.1073/pnas.1107791108

74. Peiris JS, Hui KP, Yuen HL. Host response to influenza virus: protection versus reproduction is permitted which does not comply with these terms.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 McAuley, Kedzierska, Brown and Shank. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Author/s: McAuley, JL; Kedzierska, K; Brown, LE; Shanks, GD

Title: Host immunological factors enhancing mortality of young adults during the 1918 influenza pandemic

Date: 2015-08-19

Citation: McAuley, J. L., Kedzierska, K., Brown, L. E. & Shanks, G. D. (2015). Host immunological factors enhancing mortality of young adults during the 1918 influenza pandemic. FRONTIERS IN IMMUNOLOGY, 6 (AUG), https://doi.org/10.3389/fimmu.2015.00419.

Persistent Link: http://hdl.handle.net/11343/261718

File Description: Published version

License: CC BY